Germany, Politics / LawGermany

Infectious diseases: Reacting faster and more effectively


Berlin – Germany has launched Europe’s first civil high-throughput screening facility for high-risk infectious agents within the framework of ERA-NET PathoGenoMics. The novel bio-safety level 3 (BSL3) unit at the Max Planck Institute for Infection Biology in Berlin was inaugurated in mid-September by representatives from the German Research Ministry and the Max Planck Society. The next step will be to carry out functional RNAi screens in flu-infected host cells to find new targets and drug leads.

Circumventing microbial resistance

Identification of drug candidates against multi-resistant bacterial pathogens will also be a priority for the team of Max Planck researchers under Professor Thomas Meyer. Infectious diseases are still the world’s second most frequent cause of death in spite of improvements in hygiene, vaccination campaigns and further development of antibiotics. Researchers currently use two scientific strategies to nail down promising drug candidates. The hypothesis-driven approach focusses on the investigation of distinct virulence processes, while the global analysis approach employs high-throughput technologies and bioinformatics to identify the most critical factors in pathogenesis. The latter has been gradually gaining in importance. Within the framework of ERA-NET PathoGenoMics, the Max Planck Society and German Ministry of Education and Research (BMBF) have now kicked-off Europe’s first high-throughput screening facility for highrisk pathogenic agents. The BSL3 (biosafety level) unit comprises a screening robot, as well as the necessary periphery infrastructure such as molecular biological BSL3 labs and state-of-the-art high-throughput microscopy and read-out devices. Its prime purpose will be to conduct screens with bacterial pathogens causing plague, typhus, tuberculosis and other deadly diseases.

First project: RNAi screen against pandemic influenza

The recent flu pandemic has also led to an expansion of that brief. The institute is now preparing to screen for drug candidates against pandemic influenza and is searching support from the EU FP7 HEALTH programme. Targeting host-cell compounds The researchers will be testing a new strategy for overcoming the ability of flu viruses to change their phenotype, thus escaping current therapeutic regimes. Influenza A viruses exhibit intrinsic mechanisms for generating altered viruses: their genome consists of 8 genome segments that can be quickly re-assorted upon viral coinfections, a process called antigenic shift. Such viral recombinants exhibit severely altered surface structures, allowing them to slip under the immune system’s radar. Moreover, virus replication facilitates the generation of point mutations, giving rise to a steady ‘antigenic drift’ and viral escape mutants. Such viral escape mutants clearly hamper efficacy of available flu treatments, as existing anti-virals are directed against bona fide viral targets, which risks generating therapy resistance. The new project is aimed at benefiting from the fact that viral infection and replication intimately depend on factors provided by the host cell.

Focus on targets essential for the virus

The MPI team will target host cell factors that are dispensable for the host but essential for virus replication. Using high-throughput RNA interference technology, they will scan the entire human genome for critical determinants of infection. Identification of these determinants will lead to promising therapeutic solutions for the most important human virus infections. The approach can also be applied to other viral infections with pandemic potential, according to Meyer. “During the past few decades, new viral diseases such as AIDS, SARS and Nipah Virus Encephalitis have emerged. On top of that, known viral agents are in the process of changing their behavior and location because of i.e. climatic variations or international traffic.” Meyer is convinced that the new project represents a necessary and timely search for suitable targets and effective drugs against devastating infections that have high mortality rates.



The first of February marked a milestone for Leverkusen-based Bio­frontera AG in more ways than one. It was the first day that Ameluz, the firm’s first approved product, could be sold in German pharmacies. It was also the date...



Darmstadt – German pharmaceutical and chemical company Merck KGaA has set a downbeat tone for 2012. CEO Karl-Ludwig Kley said the recently launched cost-cutting programme and tough economic conditions will weigh on profits this...



Mainz/Leuna – Two biotech concepts were amongst the winners of the recent third round of the Excellence Cluster initiative, which is funded by the German Ministry for Research. In Mainz the champagne corks popped especially loud...



German Merck KGaA has closed a licencing agreement with US-based Threshold Pharmaceuticals Inc. The cooperation centres around the hypoxia­-activated drug TH-302, which is currently being studied in a global Phase III study....



Munich – Looking back with satisfaction and bent on a prize for good behaviour, German biopharmaceutical company Wilex AG reported yesterday on the fiscal year 2011 and outlined the shores in sight. The 2011 total revenue was...



Brussels – European cartilage researchers intensify their cooperation. The 'gristle network' comprises scientists from Belgium, France, Germany and Luxembourg. Its members plan to meet regularly to exchange views and information...


Thousand Oaks/Munich - Bling bling for blinatumomab. It is a compliment for the European life sciences scene and sad news at the same time. Amgen Inc., the world's largest biotechnology company, agreed to buy Micromet Inc., an...



Martinsried - SHELTER is responsible for the fact that the stocks of 4SC behaved like a rodeo horse on Thursday. The shares rose in several stages up to 63%, only to settle at a mere 43% rise at the end of the day. SHELTER is a...



Ludwigshafen – BASF Plant Science GmbH, the agrochemistry and biotech arm of the world-largest chemistry company, thinks that it has outstayed its welcome in Europe. Over the next two years, most of the green biotechnology...



Munich - It is the accolade for Micromet. The German company, which is listed on the U.S. stock exchange, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the renowned US...

Displaying results 1 to 10 out of 454

1-10 Next >

© 2007-2016 BIOCOM


Current issue

All issues

Product of the week


Stock list

All quotes


  • ARGEN-X (B)14.20 EUR5.19%
  • MAGFORCE (D)4.71 EUR4.43%
  • DIAMYD MEDICAL -B- (S)7.20 SEK4.35%


  • BIONOR PHARMA (N)0.41 NOK-6.82%
  • PHOTOCURE (N)41.00 NOK-6.61%
  • SAREUM HOLDINGS (UK)0.74 GBP-5.13%


  • KARO BIO (S)43.10 SEK30.6%
  • MOLMED (I)0.42 EUR27.3%


  • BIONOR PHARMA (N)0.41 NOK-28.1%
  • WILEX (D)1.46 EUR-13.6%


  • NICOX (F)10.29 EUR430.4%
  • SAREUM HOLDINGS (UK)0.74 GBP236.4%
  • GENMAB (DK)1085.00 DKK81.6%


  • BB BIOTECH (D)44.30 EUR-82.9%
  • EVOCUTIS (UK)0.04 GBP-77.8%
  • CIRCASSIA LIMITED (L)92.00 GBP-73.1%

No liability assumed, Date: 30.08.2016


All Events